Immunovant, Inc. (IMVT)
UndervaluedFundamental
23
मूल्य
$33.78
मार्केट कैप
$6.98B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
argenx sells efgartigimod (Vyvgart), the first approved FcRn blocker, and competes with Immunovant's IMVT-1402 for the same autoimmune patients in myasthenia gravis, CIDP and other IgG-driven diseases.
Johnson & Johnson markets the FcRn blocker nipocalimab (Imaavy) in generalized myasthenia gravis and is expanding it into Sjögren's disease and other indications Immunovant is also targeting.
UCB's rozanolixizumab (Rystiggo) is an approved FcRn blocker for generalized myasthenia gravis, competing for the same neurologists and the same patients Immunovant's lead programme addresses.
Viridian sells veligrotug (Lumvoa) for thyroid eye disease and is developing its own FcRn inhibitors, putting it head-to-head with Immunovant in the thyroid autoimmune indications built around Graves' disease.
Biohaven is developing BHV-1300, an IgG-degrading therapy aimed at Graves' disease and other antibody-driven autoimmune conditions, the same indications Immunovant has chosen for IMVT-1402.
बैलेंस शीट और तरलता
राजस्व
0
31/3/2026 को समाप्त वित्त वर्ष
शुद्ध आय
$-506M
31/3/2026 को समाप्त वित्त वर्ष
Free Cash Flow
$-407M
कुल इक्विटी
$853M
कुल देनदारियाँ
$104M
Current Ratio
7.27
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
कोई आय डेटा उपलब्ध नहीं
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$48.88
वर्तमान मूल्य
$33.78
Margin of Safety
+30.9%
Fair Value सीमा
$46.43 - $51.32
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-59.3%
P/B Ratio
9.49
P/FCF
-
Gross Margin
-
ROIC
-
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
-
WACC
9.6%
ROIC − WACC
-
Fundamental विश्लेषण मानदंड
पास (5)
- Price CAGR 11.75%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 78% Buy
फेल (9)
- EPS shows upward trend
- P/B Ratio 9.49
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -69.6%
- Earnings Surprise avg -5.5%
- Share Dilution 20.4%
- Piotroski F-Score 2/9
अनुपलब्ध (13)
- ROIC NaN%
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 46 |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 38 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | 46 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 47 |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer | 62 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | - |
| Ms. Becky Merlina | Senior VP & Global Head of Quality | - |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | - |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | - |
Audit जोखिम
4
बोर्ड जोखिम
10
मुआवजा जोखिम
9
शेयरधारक अधिकार जोखिम
10
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-05-20
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-06
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-09-03
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for IMVT, sourced from Markets Gazette.
- 3/15/2026POSITIVEA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
A healthcare hedge fund has significantly increased its stake in Immunovant Inc., acquiring an additional $24.5 million worth of stock. Immunovant is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases. Its lead candidate is currently undergoing Phase II trials. This substantial investment by a specialized healthcare fund suggests strong conviction in the company's pipeline and future prospects. For investors, this move could signal positive upcoming developments or a favorable risk-reward profile for Immunovant's stock.
- 3/11/2026POSITIVEImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Inc. (IMVT) experienced a significant surge, with its stock price climbing 30%. This upward momentum comes despite a notable insider trimming their stake by $3 million. The company, which focuses on antibody therapies for autoimmune diseases, has seen its lead candidate advance through clinical trials. This progress in its drug development pipeline is a key driver for investor optimism, suggesting potential future revenue streams and market expansion. The stock's performance indicates strong market confidence in Immunovant's therapeutic pipeline and its long-term growth prospects, outweighing the impact of the insider's partial divestment.
via Markets Gazette